Shilpa Medicare Ltd.
NSE: SHILPAMED | BSE: 530549
₹476.20
₹-2.20
(-0.46%)
As on 18-May-2026IST
Market cap
₹9,329 Cr
Revenue (TTM)
₹1,432 Cr
P/E Ratio
62.2
P/B Ratio
3.7
Div. Yield
0.1 %
Quality Score
1/10
Growth Score
5/10
Valuation Score
3/10
Momentum Score
8/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹150 Cr
-
ROE
3.7 %
-
ROCE
6.9 %
-
Industry P/E
33.65
-
EV/EBITDA
24.3
-
Debt to Equity
0.2
-
Book Value
₹127.4
-
EPS
₹14.5
-
Face value
1
-
Shares outstanding
195,581,816
10 Years Aggregate
CFO
₹1,083.09 Cr
EBITDA
₹1,837.95 Cr
Net Profit
₹862.24 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Shilpa Medicare
| 48.3 | 16.0 | 42.7 | 34.5 | 54.6 | 13.3 | 7.1 |
|
BSE Healthcare
| 8.9 | 8.8 | 9.5 | 11.4 | 27.0 | 14.4 | 11.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Shilpa Medicare
| -21.4 | 154.6 | 18.7 | -48.0 | 19.9 | 59.3 | -28.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Shilpa Medicare
|
476.2 | 9,329.3 | 1,432.0 | 149.0 | 19.1 | 7.9 | 62.2 | 3.7 |
| 3,214.1 | 40,117.5 | 5,452.9 | 1,056.0 | 22.4 | 23.9 | 38 | 8.9 | |
| 8,513.5 | 21,254.5 | 2,177.5 | 200.9 | 11.3 | 26.5 | 105.8 | 25.6 | |
| 1,986.1 | 15,107.7 | 2,187.2 | 649.7 | 31.5 | 19 | 23.6 | 4.2 | |
| 1,340.8 | 18,572.2 | 3,078.2 | 469.4 | 26.4 | 14.9 | 43 | 5.1 | |
| 2,125.3 | 34,116.3 | 4,147.8 | 709.5 | 22.3 | 18.3 | 48.1 | 8.2 | |
| 4,859.3 | 22,234.1 | 2,519.7 | 722.4 | 33.6 | 18.8 | 30.8 | 5.3 | |
| 5,255.0 | 8,734.4 | 1,348.5 | 293.5 | 28.1 | 50.7 | 29.8 | 12.5 | |
| 3,196.9 | 7,383.7 | 1,773.8 | 309.8 | 24.0 | 43.1 | 23.8 | 9.5 | |
| 1,151.4 | 10,603.1 | 4,858.7 | 574.1 | 14.9 | 19.7 | 19.1 | 3.6 |
Shareholding Pattern
View DetailsNews & Analysis
All News
Five companies that suffered a quality dip
4 min read•By Vishal Goyal
Companies falling short of cash
2 min read•By Rajan Gulati
About Shilpa Medicare
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States,... Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers intermediates; peptides; biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, oral dissolving films, transdermal patches. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India. Read more
-
Incorporated
1987
-
Chairman
Omprakash Inani
-
Managing Director
Vishnukant Bhutada
-
Headquarters
Raichur, Karnataka
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Shilpa Medicare
What is the current share price of Shilpa Medicare Ltd Today?
The share price of Shilpa Medicare Ltd is ₹476.20 (NSE) and ₹477.00 (BSE) as of 18-May-2026 IST. Shilpa Medicare Ltd has given a return of 54.6% in the last 3 years.
What is the current PB & PE ratio of Shilpa Medicare Ltd?
The P/E ratio of Shilpa Medicare Ltd is 62.18 times as on 18-May-2026, a 85 premium to its peers’ median range of 33.65 times.
The P/B ratio of Shilpa Medicare Ltd is 3.74 times as on 18-May-2026, a 19 discount to its peers’ median range of 4.59 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
82.81
|
2.73
|
|
2024
|
125.64
|
2.21
|
|
2023
|
0.00
|
1.12
|
|
2022
|
56.83
|
1.89
|
|
2021
|
18.42
|
1.84
|
What is the 52 Week High and Low of Shilpa Medicare Ltd?
The 52-week high and low of Shilpa Medicare Ltd are Rs 500.00 and Rs 259.50 as of 19-May-2026.
What is the market cap of Shilpa Medicare Ltd?
Shilpa Medicare Ltd has a market capitalisation of ₹ 9,329 Cr as on 18-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Shilpa Medicare Ltd?
Before investing in Shilpa Medicare Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.